中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (9): 697-702.doi: 10.12144/zgmfskin202509697

• 综述 • 上一篇    

Janus激酶抑制剂在自身免疫性大疱病中的应用进展

仝海男1,郭建辉1,2   

  1. 1河北中医药大学中医外科学教研室，河北石家庄，050001； 2河北省沧州中西医结合医院皮肤科，河北沧州，061001
  • 出版日期:2025-09-15 发布日期:2025-09-08

Research progress on the application of Janus kinase inhibitors in autoimmune bullous diseases

TONG Hainan1, GUO Jianhui1,2   

  1. 1 Department of Traditional Chinese Medicine and Surgery, Hebei University of Traditional Chinese Medicine, Shijiazhuang 050001，China; 2 Department of Dermatology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou 061001，China
  • Online:2025-09-15 Published:2025-09-08

PDF (PC)

64

摘要： 自身免疫性大疱病（autoimmune blistering diseases, AIBD）是一组由自身抗体介导的皮肤黏膜水疱性疾病，传统治疗以糖皮质激素和免疫抑制剂为主。近年来，JAK抑制剂因其靶向调控JAK-STAT信号通路、阻断炎症和免疫反应的特性，成为新兴研究方向。本文综述了JAK-STAT通路在AIBD发病机制中的作用，重点探讨了芦可替尼、托法替布、乌帕替尼等JAK抑制剂在治疗天疱疮、类天疱疮中的临床应用。

关键词: JAK抑制剂, 自身免疫性大疱病, 天疱疮, 类天疱疮, JAK/STAT信号通路

Abstract: Autoimmune blistering diseases (AIBD) are a group of autoimmune antibody-mediated blistering disorders affecting the skin and mucous membranes. Traditional treatments mainly rely on glucocorticoids and immunosuppressants. In recent years, JAK inhibitors have emerged as a promising research direction due to their properties of targeting and regulating the JAK-STAT signaling pathway, as well as blocking inflammatory and immune responses. The role of the JAK-STAT pathway in the pathogenesis of AIBD are reviewed in this paper, with a focus on the clinical applications of JAK inhibitors such as ruxolitinib, tofacitinib, and upadacitinib in the treatment of pemphigus and pemphigoid.

Key words: Janus kinase inhibitor, autoimmune bullous diseases, pemphigus, pemphigoid, JAK-STAT signaling pathway